Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Revvity ( (RVTY) ) is now available.
Revvity reported first-quarter 2026 results on May 5, 2026, with revenue rising to $711 million from $665 million a year earlier and GAAP EPS from continuing operations improving to $0.37 from $0.35. Adjusted EPS from continuing operations increased to $1.06, while adjusted operating profit margins narrowed to 23.6% from 25.6%, reflecting solid top-line growth but some pressure on profitability.
On a pro forma basis, which excludes the China Immunodiagnostics business, revenue reached $687 million and pro forma adjusted EPS climbed to $1.04, with pro forma organic revenue growth of 6% supported by stronger performance in diagnostics. Segment results showed Life Sciences revenue up 6% and Diagnostics revenue up 8% year over year, with both segments delivering modest adjusted operating income declines as margins eased.
The company also unveiled a strategic plan to divest its China Immunodiagnostics business, which accounted for roughly 6% of 2025 revenue, signing a letter of intent on April 16, 2026, and targeting completion of the sale in 2027 subject to regulatory approvals. This move is part of a broader portfolio-optimization strategy and will reorient Revvity’s financial reporting and guidance on a pro forma basis that excludes the business slated for divestiture.
Revvity updated its full-year 2026 outlook on a pro forma basis, forecasting revenue of $2.81 billion to $2.84 billion, pro forma organic revenue growth of 3% to 4%, and pro forma adjusted EPS of $5.20 to $5.30. Management emphasized that the first-quarter performance exceeded internal expectations for organic growth and adjusted EPS and framed the planned divestiture as a step to sharpen the company’s focus and enhance longer-term shareholder returns.
The most recent analyst rating on (RVTY) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Revvity stock, see the RVTY Stock Forecast page.
Spark’s Take on RVTY Stock
According to Spark, TipRanks’ AI Analyst, RVTY is a Neutral.
The score is primarily supported by solid financial performance (strong cash generation and improved leverage) and a cautiously constructive earnings outlook with EPS/FCF support. These positives are offset by weak technicals (price below key moving averages and negative MACD) and a valuation that looks somewhat premium with a very low dividend yield.
To see Spark’s full report on RVTY stock, click here.
More about Revvity
Revvity, Inc., listed on the NYSE under the ticker RVTY, operates in the health sciences sector, providing solutions, technologies, expertise and services that support workflows from discovery and development to diagnostics. The company’s portfolio spans life sciences and diagnostics, targeting global research, clinical and industrial customers seeking integrated, workflow-based offerings.
The business is organized into Life Sciences and Diagnostics segments, which together generated $711 million in revenue in the first quarter of 2026. Life Sciences contributed $362 million, while Diagnostics delivered $349 million, with both segments posting mid‑single‑digit revenue growth year over year and maintaining high‑teens to high‑20s adjusted operating margins despite some margin compression.
Average Trading Volume: 1,129,330
Technical Sentiment Signal: Sell
Current Market Cap: $9.67B
See more insights into RVTY stock on TipRanks’ Stock Analysis page.